Acute Coronary Syndrome of Embolic Origin in a Patient on Direct Thrombin Inhibitor Three Years After Mechanical Mitral Valve Replacement

Andrew Kei-yan Ng, Man Hong Jim

Abstract


Dabigatran was shown to be inferior to warfarin for patients with mechanical heart valves.  However it was postulated that its inferiority was limited to early post-operative period where the valves had not been adequately endothelialized.  We present a case where thromboembolic acute coronary syndrome developed in a patient six months after switching from warfarin to dabigatran, despite three years after mechanical mitral valve replacement.  We propose an alternative explanation for dabigatran failure. 


Keywords


Dabigatran; Mechanical heart valves; Acute coronary syndrome

Full Text:

Ng 295 pp106-107

References


Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-41.

-------------------------------------------------------

Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart Association/American College of Cardiology F. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Journal of the American College of Cardiology 2003;41:1633-52.

-------------------------------------------------------

Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50. DOI:10.1161/CIRCULATIONAHA.110.004424

-------------------------------------------------------

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. DOI: 10.1056/NEJMoa0905561

-------------------------------------------------------

Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14. DOI: 10.1056/NEJMoa1300615

-------------------------------------------------------

Walker CP, Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth 2002;88:848-63.

-------------------------------------------------------

Kaeberich A, Reindl I, Raaz U, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis 2011;32:417-25. DOI: 10.1007/s11239-011-0621-6

-------------------------------------------------------

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4




DOI: https://doi.org/10.17987/icfj.v8i0.295

Copyright (c) 2016 Andrew Kei-yan Ng, Man Hong Jim

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.